|
| Status |
Public on Sep 30, 2013 |
| Title |
marrow CD3 T cells_pre_NR1 (nonresponder) |
| Sample type |
RNA |
| |
|
| Source name |
marrow derived CD3+ T cells, before DLI
|
| Organism |
Homo sapiens |
| Characteristics |
patient: nonresponder
cell type: bone marrow-derived CD3+ T cells
patient: nonresponder
cell type: bone marrow-derived CD3+ T cells
|
| Treatment protocol |
BMMCs from DLI responders and nonresponders were thawed, and CD3+ T cells were enriched using magnetic bead sorting (Miltenyi Biotec).
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Trizol extraction of total RNA was performed according to the manufacturer's instructions.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).
|
| |
|
| Hybridization protocol |
Total RNA was amplified followed by cDNA synthesis (Ovation Pico WTA System V2, NuGEN, San Carlos, CA) and samples were hybridized to Affymetrix U133A+ 2.0 arrays (Santa Cruz, CA) at the DFCI Microarray Core Facility
|
| Scan protocol |
GeneChips were scanned using the Affymetrix GeneChip Scanner 3000.
|
| Description |
Gene expression data from marrow derived CD3+ T cells in non-responder (NR1) before DLI
|
| Data processing |
The data were analyzed using Robust Multichip Average (RMA) as in implemented in the R package affy. Probe level data were averaged to the gene level, and the resulting values were converted to a log2 scale for downstream analysis.
|
| |
|
| Submission date |
Jul 21, 2013 |
| Last update date |
Sep 30, 2013 |
| Contact name |
Pavan Bachireddy |
| E-mail(s) |
[email protected]
|
| Organization name |
Dana-Farber Cancer Institute
|
| Lab |
Catherine Wu, MD
|
| Street address |
77 Avenue Louis Pasteur
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02115 |
| Country |
USA |
| |
|
| Platform ID |
GPL571 |
| Series (1) |
| GSE49067 |
Expression data from responders/nonresponders before/after receiving DLI for relapse of CML s/p BMT |
|
